-
1
-
-
84856950170
-
-
Genentech, Inc. (trastuzumab).South San Francisco, CA: Genentech, Inc. Accessed October 7, 2010
-
Genentech, Inc. Prescribing Information for Herceptin (trastuzumab).South San Francisco, CA: Genentech, Inc, 2009. http://www.gene.com/gene/products/ information/pdf/herceptinprescribing.pdf. Accessed October 7, 2010.
-
(2009)
Prescribing Information for Herceptin
-
-
-
2
-
-
34347395733
-
Trastuzumab - Mechanism of action and use in clinical practice
-
DOI 10.1056/NEJMra043186
-
Hudis CA. Trastuzumab-Mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51. (Pubitemid 47026733)
-
(2007)
New England Journal of Medicine
, vol.357
, Issue.1
, pp. 39-51
-
-
Hudis, C.A.1
-
3
-
-
0029991439
-
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
-
Baselga J, Tripathy D,Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-744.
-
(1996)
J. Clin. Oncol.
, Issue.14
, pp. 737-744
-
-
Baselga, J.1
Tripathy, D.2
Mendelsohn, J.3
Baughman, S.4
Benz, C.C.5
Dantis, L.6
Sklarin, N.T.7
Seidman, A.D.8
Hudis, C.A.9
Moore, J.10
Rosen, P.P.11
Twaddell, T.12
Henderson, I.C.13
Norton, L.14
-
4
-
-
0032850677
-
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
-
Cobleigh MA, Vogel CL, Tripathy D, Nicholas RJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648. (Pubitemid 29415219)
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.9
, pp. 2639-2648
-
-
Cobleigh, M.A.1
Vogel, C.L.2
Tripathy, D.3
Robert, N.J.4
Scholl, S.5
Fehrenbacher, L.6
Wolter, J.M.7
Paton, V.8
Shak, S.9
Lieberman, G.10
Slamon, D.J.11
-
5
-
-
0036467826
-
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
-
DOI 10.1200/JCO.20.3.719
-
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, SlamonDJ,MurphyM,Novotny WF, Burchmore M, Shak S, Stewart SJ, PressM. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726. (Pubitemid 34111379)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.3
, pp. 719-726
-
-
Vogel, C.L.1
Cobleigh, M.A.2
Tripathy, D.3
Gutheil, J.C.4
Harris, L.N.5
Fehrenbacher, L.6
Slamon, D.J.7
Murphy, M.8
Novotny, W.F.9
Burchmore, M.10
Shak, S.11
Stewart, S.J.12
Press, M.13
-
6
-
-
0346017700
-
Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel
-
DOI 10.1200/JCO.2003.12.109
-
Leyland-Jones B, Gelman K, Ayoub J-P, Arnold A, Verma S, Dias R, Ghahramani P. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003;21:3965-3971. (Pubitemid 46606210)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.21
, pp. 3965-3971
-
-
Leyland-Jones, B.1
Gelmon, K.2
Ayoub, J.-P.3
Arnold, A.4
Verma, S.5
Dias, R.6
Ghahramani, P.7
-
7
-
-
17144371333
-
Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule
-
DOI 10.1200/JCO.2005.01.014
-
Baselga J, Carbonell X, Castaneda-Soto N-J, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23:2162-2171. (Pubitemid 46218708)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.10
, pp. 2162-2171
-
-
Baselga, J.1
Carbonell, X.2
Castaneda-Soto, N.-J.3
Clemens, M.4
Green, M.5
Harvey, V.6
Morales, S.7
Barton, C.8
Ghahramani, P.9
-
8
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2
-
DOI 10.1056/NEJM200103153441101
-
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, EiermannW, Wolter J, PegramM, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792. (Pubitemid 32222155)
-
(2001)
New England Journal of Medicine
, vol.344
, Issue.11
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
Fuchs, H.4
Paton, V.5
Bajamonde, A.6
Fleming, T.7
Eiermann, W.8
Wolter, J.9
Pegram, M.10
Baselga, J.11
Norton, L.12
-
9
-
-
22344446208
-
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group
-
DOI 10.1200/JCO.2005.04.173
-
Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra J-M. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-4274. (Pubitemid 46207001)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.19
, pp. 4265-4274
-
-
Marty, M.1
Cognetti, F.2
Maraninchi, D.3
Snyder, R.4
Mauriac, L.5
Tubiana-Hulin, M.6
Chan, S.7
Grimes, D.8
Anton, I.9
Lluch, A.10
Kennedy, J.11
O'Byrne, K.12
Conte, P.13
Green, M.14
Ward, C.15
Mayne, K.16
Extra, J.-M.17
-
10
-
-
72449139053
-
Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: The J017360 trial group
-
Inoue K, Nakagami K, Mizutani M, Hozumi Y, Fujiwara Y, Masuda N, Tsukamoto F, Saito M, Miura S, Eguchi K, Shinkai T, Ando M, Watanabe T, Masuda N, Ohashi Y, Sano M, Noguchi S. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the J017360 trial group. Breast Cancer Res Treat 2010;119:127-136.
-
(2010)
Breast Cancer Res. Treat.
, vol.119
, pp. 127-136
-
-
Inoue, K.1
Nakagami, K.2
Mizutani, M.3
Hozumi, Y.4
Fujiwara, Y.5
Masuda, N.6
Tsukamoto, F.7
Saito, M.8
Miura, S.9
Eguchi, K.10
Shinkai, T.11
Ando, M.12
Watanabe, T.13
Masuda, N.14
Ohashi, Y.15
Sano, M.16
Noguchi, S.17
-
11
-
-
84856973156
-
-
Surveillance, Epidemiology, and End Results (SEER) Program) SEER.*Stat Database: Incidence-SEER 17 Nov Sub (1973-2006 varying) - Linked To County Attributes-Total U.S., 1969-2006 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009, based on the November 2008 submission
-
Surveillance, Epidemiology, and End Results (SEER) Program) (www.seer.cancer.gov) SEER.*Stat Database: Incidence-SEER 17 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2008 Sub (1973-2006 varying) - Linked To County Attributes-Total U.S., 1969-2006 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009, based on the November 2008 submission.
-
(2008)
Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases
-
-
-
12
-
-
0038478965
-
Overview of SEER-Medicare data: Content research applications and generalizability to the United States elderly population
-
Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Medical Care 2002;40(suppl):IV-3-IV-18.
-
(2002)
Medical Care
, vol.40
-
-
Warren, J.L.1
Klabunde, C.N.2
Schrag, D.3
Bach, P.B.4
Riley, G.F.5
-
13
-
-
64549145652
-
-
National Cancer Institute NCI Internet]. Bethesda MD:NCI Accessed October 7, 2010.
-
National Cancer Institute (NCI).Overview of the SEER program[ Internet]. Bethesda, MD:NCI, 2010. http://seer.cancer.gov/ about. Accessed October 7, 2010.
-
(2010)
Overview of the SEER program
-
-
-
14
-
-
84856947660
-
-
National Cancer Institute (NCI). SEER-Medicare: Internet]. Bethesda MD: NCI Accessed October 7, 2010
-
National Cancer Institute (NCI). SEER-Medicare: How the SEER & Medicare data are Linked [Internet]. Bethesda, MD: NCI, 2010. http://healthservices.cancer.gov/seermedicare/overview/linked.html. Accessed October 7, 2010.
-
(2010)
How the SEER & Medicare data are Linked
-
-
-
15
-
-
0036674386
-
Identifying cancer relapse using SEER-Medicare Data
-
Earle CC, Nattinger AB, Potosky AL, Lang K,Mallick R, BergerM, Warren JL. Identifying cancer relapse using SEER-Medicare Data. Medical Care 2002;40(8)(suppl):IV-75-IV-81.
-
(2002)
Medical Care
, vol.40
, Issue.8 SUPPL.
-
-
Earle, C.C.1
Nattinger, A.B.2
Potosky, A.L.3
Lang, K.4
Mallick, R.5
Berger, M.6
Warren, J.L.7
-
16
-
-
41549150295
-
Ten-year survival and cost following breast cancer recurrence: Estimates from SEER-Medicare data
-
DOI 10.1111/j.1524-4733.2007.00226.x
-
Stokes ME, Thompson D, Montoya EL, Weinstein MC, Winder EP, Earle CC. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-Medicare data. Value in Health 2008;11:213-220. (Pubitemid 351473603)
-
(2008)
Value in Health
, vol.11
, Issue.2
, pp. 213-220
-
-
Stokes, M.E.1
Thompson, D.2
Montoya, E.L.3
Weinstein, M.C.4
Winer, E.P.5
Earle, C.C.6
-
17
-
-
78649684237
-
-
(PMIC).ICD-9-CM, 6th ed. Los Angeles, CA: Practice Management Information Corporation
-
Practice Management Information Corporation (PMIC).ICD-9-CM, 6th ed. Los Angeles, CA: Practice Management Information Corporation, 2005.
-
(2005)
Practice Management Information Corporation
-
-
-
19
-
-
17144451481
-
Utility of the SEER-Medicare data to identify chemotherapy use
-
Warren JL, Harlan LC, Fahey BA, Freeman JL, Klabunde CN, Cooper GS, Knopf KB. Utility of the SEER-Medicare data to identify chemotherapy use. Medical Care 2002;40(8)(suppl):IV-55-IV-61.
-
(2002)
Medical Care
, vol.40
, Issue.8 SUPPL.
-
-
Warren, J.L.1
Harlan, L.C.2
Fahey, B.A.3
Freeman, J.L.4
Klabunde, C.N.5
Cooper, G.S.6
Knopf, K.B.7
-
20
-
-
84856972877
-
-
National Cancer Institute NCI internet]. Bethesda MD: NCI Accessed July 12, 2010.
-
National Cancer Institute (NCI).Procedure codes for SEERMedicare analysis [internet]. Bethesda, MD: NCI, 2010. http://healthservices.cancer.gov/ seermedicare/considerations/procedure-codes.html. Accessed July 12, 2010.
-
(2010)
Procedure codes for Seer Medicare analysis
-
-
-
21
-
-
78649525226
-
-
Res DAC Research Data Assistance Center Minneapolis, MN: ResDAC
-
ResDAC Research Data Assistance Center. CMS 301: Using SEER/Medicare data for research. Minneapolis, MN: ResDAC.
-
CMS 301: Using SEER/Medicare data for research
-
-
-
22
-
-
47249165270
-
Limits of observational data in dertermining outcomes from cancer therapy
-
Giordano SH, Kuo Y-F, Duan Z, Hortobagyi, GN, Freeman J, Goodwin JS. Limits of observational data in dertermining outcomes from cancer therapy. Cancer 2008;112:2456-2466.
-
(2008)
Cancer
, vol.112
, pp. 2456-2466
-
-
Giordano, S.H.1
Kuo, Y.-F.2
Duan, Z.3
Hortobagyi, G.N.4
Freeman, J.5
Goodwin, J.S.6
-
23
-
-
0034531923
-
Development of a comorbidity index using physician claims data
-
DOI 10.1016/S0895-4356(00)00256-0, PII S0895435600002560
-
Klabunde CN, Potosky AL, Legler JM,Warren JL.Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258-1267. (Pubitemid 32007842)
-
(2000)
Journal of Clinical Epidemiology
, vol.53
, Issue.12
, pp. 1258-1267
-
-
Klabunde, C.N.1
Potosky, A.L.2
Legler, J.M.3
Warren, J.L.4
-
24
-
-
0003612597
-
-
Fritz A, Ries L, (eds.). 3rd edition Bethesda, MD: Cancer Statistics Branch, SurveillanceProgram, Div of Cancer Control and Pop Sciences, National Cancer Institute, National Institutes of Health, Public Health Service, U.S. Deptartment of Health and Human Services Accessed October 7, 2010
-
Fritz A, Ries L, (eds.). SEER Program Code Manual, 3rd edition. Bethesda, MD: Cancer Statistics Branch, SurveillanceProgram, Div of Cancer Control and Pop Sciences, National Cancer Institute, National Institutes of Health, Public Health Service, U.S. Deptartment of Health and Human Services, 1998. http://seer.cancer.gov/manuals/codeman.pdf. Accessed October 7, 2010.
-
(1998)
SEER Program Code Manual
-
-
-
25
-
-
79953713795
-
-
National Cancer Institute NCI Bethesda MD: Author. Accessed May 25
-
National Cancer Institute (NCI).SAS macro to remove unreliable diagnosis coding. Bethesda, MD: Author. http://healthservices. cancer.gov/seermedicare/ program/remove.ruleout.dxcodes.macro.txt. Accessed May 25, 2010.
-
(2010)
SAS Macro to Remove Unreliable Diagnosis Coding
-
-
-
26
-
-
84856970118
-
SAS macro to calculate a comorbidity index for a patient with respect to cancer
-
National Cancer Institute (NCI). Accessed May 25
-
National Cancer Institute (NCI).SAS macro to calculate a comorbidity index for a patient with respect to cancer. NCI http://healthservices.cancer. gov/seermedicare/program/charlson.comorbidity.macro.txt. Accessed May 25, 2010.
-
(2010)
NCI
-
-
-
27
-
-
0023092594
-
A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
-
DOI 10.1016/0021-9681(87)90171-8
-
Charlson ME, Pompei P, Ales KL,MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40(5):373-383. (Pubitemid 17055592)
-
(1987)
Journal of Chronic Diseases
, vol.40
, Issue.5
, pp. 373-383
-
-
Charlson, M.E.1
Pompei, P.2
Ales, K.A.3
MacKenzie, C.R.4
-
28
-
-
0026639706
-
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
-
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
-
(1992)
J. Clin. Epidemiol.
, vol.45
, pp. 613-619
-
-
Deyo, R.A.1
Cherkin, D.C.2
Ciol, M.A.3
-
29
-
-
0028227007
-
A comparison of administrative versus clinical data: Coronary artery bypass surgery as an example
-
DOI 10.1016/0895-4356(94)90006-X
-
Romano PS, Roos LL, Luft HS, Jollis JG, Doliszny K. A comparison of administrative versus clinical data: coronary artery bypass surgery as an example. J Clin Epidemiol 1994;47:249-260. (Pubitemid 24109737)
-
(1994)
Journal of Clinical Epidemiology
, vol.47
, Issue.3
, pp. 249-260
-
-
Romano, P.S.1
Roos, L.L.2
Luft, H.S.3
Jollis, J.G.4
Doliszny, K.5
-
30
-
-
79952035882
-
Using claimsbased measures to predict performance status score in patients with lung cancer
-
Salloum RG, Smith TJ, Jensen GA, Elston Lafata J. Using claimsbased measures to predict performance status score in patients with lung cancer. Cancer 2010;117:1038-1048.
-
(2010)
Cancer
, vol.117
, pp. 1038-1048
-
-
Salloum, R.G.1
Smith, T.J.2
Jensen, G.A.3
Elston Lafata, J.4
-
31
-
-
0036674454
-
Studying radiation therapy using SEER-Medicarelinked data
-
Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J. Studying radiation therapy using SEER-Medicarelinked data. Medical Care 2002;40(8)(suppl):IV-49-IV-54.
-
(2002)
Medical Care
, vol.40
, Issue.8 SUPPL.
-
-
Virnig, B.A.1
Warren, J.L.2
Cooper, G.S.3
Klabunde, C.N.4
Schussler, N.5
Freeman, J.6
-
32
-
-
0030862072
-
Estimating causal effects from large data sets using propensity scores
-
Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-763. (Pubitemid 27446562)
-
(1997)
Annals of Internal Medicine
, vol.127
, Issue.8 SUPPL.
, pp. 757-763
-
-
Rubin, D.B.1
-
33
-
-
39349101029
-
Immortal time bias in pharmacoepidemiology
-
DOI 10.1093/aje/kwm324
-
Suissa S. Immortal time bias in pharmacoepidemiology. AmJ Epidemiol 2008;167:492-499. (Pubitemid 351264145)
-
(2008)
American Journal of Epidemiology
, vol.167
, Issue.4
, pp. 492-499
-
-
Suissa, S.1
-
34
-
-
77955872497
-
Lasagna plots: A saucy alternative to spagetti plots
-
Swihart BJ, Caffo B, James BD, Strand M, Schwartz BS, Punjabi NM. Lasagna plots: a saucy alternative to spagetti plots. Epidemiology 2010;21(5):621-625.
-
(2010)
Epidemiology
, vol.21
, Issue.5
, pp. 621-625
-
-
Swihart, B.J.1
Caffo, B.2
James, B.D.3
Strand, M.4
Schwartz, B.S.5
Punjabi, N.M.6
-
35
-
-
78649829808
-
Comparative effectiveness of prostate cancer treatments: Evaluating statistical adjustments for confounding in observational data
-
Hadley J, Yabroff KR, Barrett MJ, Penson DF, Saigal CS, Potosky AL. Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst 2010;102:1780-1793.
-
(2010)
J. Natl. Cancer Inst.
, vol.102
, pp. 1780-1793
-
-
Hadley, J.1
Yabroff, K.R.2
Barrett, M.J.3
Penson, D.F.4
Saigal, C.S.5
Potosky, A.L.6
-
36
-
-
70649113093
-
A most stubborn bias: No adjustment method fully resolves confounding by indicationin observational studies
-
Bosco JLF, Silliman RA, Thwin SS, Geiger AM, Buist DS, Prout MN, Yood MU, Haque R, Wei F, Lash TL. A most stubborn bias: no adjustment method fully resolves confounding by indicationin observational studies. J Clin Epidemiol. 2010;63:64-74.
-
(2010)
J. Clin. Epidemiol.
, vol.63
, pp. 64-74
-
-
Bosco, J.L.F.1
Silliman, R.A.2
Thwin, S.S.3
Geiger, A.M.4
Buist, D.S.5
Prout, M.N.6
Yood, M.U.7
Haque, R.8
Wei, F.9
Lash, T.L.10
-
37
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182. (Pubitemid 17231334)
-
(1987)
Science
, vol.235
, Issue.4785
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
-
38
-
-
84856960931
-
-
Accessed October 7, 2010
-
Siegel J. Approval of biologics license application for Trastuzumab, 1998. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm091360.pdf. Accessed October 7, 2010.
-
(1998)
Approval of Biologics License Application for Trastuzumab
-
-
Siegel, J.1
-
39
-
-
0033159326
-
The utility of Medicare claims data for measuring cancer stage
-
Cooper GS, Yuan Z, Stange KC, Amini SB, Dennis LK, Rimm AA. The utility of Medicare claims data for measuring cancer stage. Medical Care 1999;37(7):706-711.
-
(1999)
Medical Care
, vol.37
, Issue.7
, pp. 706-711
-
-
Cooper, G.S.1
Yuan, Z.2
Stange, K.C.3
Amini, S.B.4
Dennis, L.K.5
Rimm, A.A.6
-
40
-
-
19344364880
-
Effects of chemotherapy and hormonal therapy for early breast cancer onrecurrence and 15-year survival: Anoverviewof the randomized trials
-
Early Breast Cancer Trialists' Collaborative Group (EBCTCG
-
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).Effects of chemotherapy and hormonal therapy for early breast cancer onrecurrence and 15-year survival: anoverviewof the randomized trials. Lancet 2005;365(9472):1687-1717.
-
(2005)
Lancet
, vol.365
, Issue.9472
, pp. 1687-1717
-
-
|